Angion Biomedica (Angion Biomedica) Forward Dividend Yield % : 0.00% (As of May. 17, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Angion Biomedica Forward Dividend Yield %?

As of today (2024-05-17), the Forward Annual Dividend Yield of Angion Biomedica is 0.00%.

As of today (2024-05-17), the Trailing Annual Dividend Yield of Angion Biomedica is 0.00%.

ANGN's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.51
* Ranked among companies with meaningful Forward Dividend Yield % only.

Angion Biomedica's Dividends per Share for the three months ended in Mar. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Angion Biomedica's Forward Dividend Yield %

For the Biotechnology subindustry, Angion Biomedica's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Angion Biomedica's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Angion Biomedica's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Angion Biomedica's Forward Dividend Yield % falls into.

Angion Biomedica Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Angion Biomedica (NAS:ANGN) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Angion Biomedica Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Angion Biomedica's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Angion Biomedica (Angion Biomedica) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Angion Biomedica Corp (NAS:ANGN) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

7-57 Wells Avenue, Suite 14, Newton, MA, USA, 02459

Website

https://www.angion.com

Angion Biomedica Corp is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Its product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other major organs, such as the lungs, central nervous system (CNS) and heart; acute lung injury (ALI), with a primary focus on acute respiratory distress syndrome (ARDS), and acute CNS injuries. It is advancing multiple programs for the treatment of fibrotic diseases, leading to ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).

Executives

Jay Venkatesan	director, officer: See Remarks	C/O AYER CAPITAL MANAGEMENT, LP, 230 CALIFORNIA ST, SUITE 600, SAN FRANCISCO CA 94111
Allen Nissenson	director	601 HAWAII ST., EL SEGUNDO CA 90245
John F. Neylan	officer: See Remarks	750 LEXINGTON AVENUE, NEW YORK NY 10022
Gregory S Curhan	officer: See Remarks	600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Jennifer J Rhodes	officer: See Remarks	C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608
Itzhak Goldberg	officer: See Remarks	51 CHARLES LINDBERGH BLDV., UNIONDALE NY 11553
Victor F Ganzi	director
Gilbert S Omenn	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Karen J Wilson	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Eisa-abc Llc	10 percent owner	C/O ANGION BIOMEDICA CORP., 51 CHARLES LINDBERGH BOULEVARD, UNIONDALE NY 11553